• Dry Eye Treatments Show Fast Relief and Lasting Safety

    https://www.optometrytimes.com/view/aaopt-2026-new-dry-eye-data-perfluorohexyloctane-relief-cyclosporine-safety

    New research presented at the American Academy of Optometry Annual Meeting looked at two common dry eye treatments. In a real-world analysis of patients newly prescribed perfluorohexyloctane (PFHO, brand name Miebo), average symptom scores dropped meaningfully within two weeks of starting treatment and continued improving by the four-week mark. Every symptom tracked, including dryness, burning, light sensitivity, and blurred vision, showed a significant reduction at both checkpoints.

    A separate 12-month trial in 204 patients looked at the long-term safety of cyclosporine ophthalmic solution 0.1%, a different class of dry eye medication, and found no meaningful loss of corneal endothelial cells, the cells that keep the cornea clear, over a full year of twice-daily use. Together, these findings give both patients and providers more confidence in two of the most commonly prescribed dry eye therapies. If drops or artificial tears haven’t been cutting it for your dry eye symptoms, ask us about these treatment options at your next visit.

    Book your child’s exam at Tigard Eyecare today: (503) 639-8632.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.